Suspension hepatocytes are presented in the MileCell product brochure as an in vitro model for drug metabolism and uptake studies. For research teams comparing compounds, species, strains, or cell lots, the central questions are practical: does the selected lot retain measurable metabolic activity after thawing, is the relevant Phase I or Phase II pathway characterized, and is there metabolic-stability evidence that matches the planned workflow?
The brochure addresses these questions through post-thaw quality control, functional characterization, enzyme-activity data, metabolic-stability curves, broad animal-species coverage, and configurable product options. This article organizes that source material into a focused guide for using suspension hepatocytes in drug metabolism testing. No third-party product data or performance claims have been added.
What Are Suspension Hepatocytes?
The brochure describes primary suspension hepatocytes as cryopreserved hepatocytes used in suspended-cell cultures for drug metabolism and uptake studies. Before batch release, the products undergo quality control and functional characterization. The listed portfolio entries are pooled, suspension-format, metabolism-qualified products supplied at 5 million cells per vial.
MileCell attributes hepatocyte quality to optimized tissue harvesting protocols, enhanced cell-isolation techniques, and post-thaw functional characterization intended to support viability, purity, structural integrity, and reliable in vitro performance. The brochure does not provide a universal numerical viability specification, so no viability percentage is stated in this article.
Why Functional Characterization Matters in Drug Metabolism Testing
Drug metabolism testing depends on the metabolic pathways represented by the selected cells and on the evidence available for the exact lot or product format. The brochure therefore highlights characterization of key CYP, SULT, and UGT enzymes and presents both metabolic-activity and metabolic-stability data for CD-1 mouse suspension hepatocytes.
| Selection principle：Match the study endpoint to the available functional evidence: enzyme-activity data for the relevant pathway, metabolic-stability data for the intended substrate approach, and the species, strain, gender, pack size, batch size, and cell specification required by the study. |
Quick Reference: Evaluating Suspension Hepatocytes
| Evaluation Area | Key Question | Brochure-Supported Information |
| Metabolic activity | Are the relevant Phase I or Phase II pathways characterized? | CYP, SULT, and UGT characterization; CD-1 mouse Phase I and Phase II activity example. |
| Metabolic stability | Is there a time-course example for the assay type? | 1 μM 7-hydroxycoumarin and verapamil curves analyzed by LC-MS/MS. |
| Lot comparison | Is consistency evaluated across lots? | Metabolic activity shown for lots CD-1477, CD-1488, CD-1499, CD-1500, and CD-1511. |
| Species selection | Which species and strains are listed? | Mouse, rat, dog, monkey, minipig, rabbit, feline, hamster, and guinea pig options. |
| Product configuration | What format and size are listed? | Pooled, suspension, metabolism qualified; 5 million cells for the listed portfolio entries. |
| Customization | Which selection fields can be discussed? | Gender, species, pack size, batch size, and cell specifications. |
Key Features of MileCell Suspension Hepatocytes
1. High Post-Thaw Viability
The brochure lists high post-thaw viability as a product feature. It does not provide a single numerical threshold in the supplied material, so lot selection should rely on the available product and functional information rather than an assumed universal value.
2. Characterization of Key Phase I and Phase II Enzymes
The brochure lists characterization of CYP, SULT, and UGT enzymes. Its CD-1 mouse example shows Phase I readouts for CYP1A, CYP3A, CYP2B, and CYP2C and Phase II readouts for UGT, ST, and UGT1A1.
3. Large Batch Size to Minimize Lot-to-Lot Variation
Large batch size is presented as a way to minimize lot-to-lot variation. The brochure also displays metabolic activity across five CD-1 mouse lots, providing a lot-comparison example.
4. Broad Species and Strain Coverage
The suspension portfolio includes mouse, rat, dog, monkey, minipig, rabbit, feline, hamster, and guinea pig products, with multiple strains or breeds listed for several species.
5. Configurable Product Options
The brochure lists customizable options for gender, species, pack size, batch size, and cell specifications. The detailed suspension portfolio contains male, female, and mixed-gender entries where shown.
6. Quality Control Before Batch Release
The brochure states that cryopreserved suspension hepatocytes undergo rigorous quality control and functional characterization before batch release to support consistent and reliable cell lots.
Experimental Data from the Product Brochure
Metabolic Activity Across Five CD-1 Mouse Lots
CD-1 Mouse Suspension Hepatocytes were thawed and incubated at 37°C at a cell concentration of 0.5 x 10^6 cells/mL. Metabolic activities were measured by LC-MS/MS and recorded as pmol/min/10^6 cells. The figure compares lots CD-1477, CD-1488, CD-1499, CD-1500, and CD-1511.
Figure 1. Phase I and Phase II metabolic activity in five CD-1 mouse suspension hepatocyte lots. Phase I readouts shown are CYP1A/phenacetin, CYP3A/testosterone, CYP3A/midazolam, CYP2B/bupropion, and CYP2C/S-mephenytoin. Phase II readouts shown are UGT/7-HC, ST/7-HC, and UGT1A1/beta-estradiol. Conditions: 37°C, 0.5 x 10^6 cells/mL; LC-MS/MS; activity reported as pmol/min/10^6 cells. The brochure states that the results demonstrate consistently replicable metabolic activity among different lots.
Metabolic Stability of 7-Hydroxycoumarin and Verapamil
The brochure evaluates the metabolic stability of 7-hydroxycoumarin and verapamil in CD-1 Mouse Suspension Hepatocytes. Each substrate is shown at 1 μM. Following incubation of thawed cells with the substrate, samples were collected at multiple time points and analyzed by LC-MS/MS. The graphs report percentage remaining over an incubation period extending to 120 minutes.
Figure 2. Metabolic stability of 1 μM 7-hydroxycoumarin and 1 μM verapamil in CD-1 mouse suspension hepatocytes. Thawed cells were incubated with substrate, samples were collected at multiple time points, and remaining substrate was analyzed by LC-MS/MS. The figure presents percentage remaining through 120 minutes; no unreported numerical values have been inferred from the curves.
Practical Considerations for Product Selection
The brochure supports a structured selection process rather than a one-size-fits-all choice. The following fields can be confirmed from the product portfolio before selecting a suspension hepatocyte product:
· Species and strain or breed.
· Gender option shown for the selected catalog entry.
· Pooled suspension format and metabolism-qualified status.
· 5 million-cell vial size for the listed products.
· Pack size, batch size, and cell-specification requirements.
· Relevant functional characterization, including enzyme activity or metabolic-stability evidence.
| Species group | Strains or breeds listed in the suspension portfolio |
| Mouse | C57BL/6N, C57BL/6JNifdc, CD-1, BALB/c, BALB/c Nude, M-NSG |
| Rat | SD, Wistar, Wistar Han, Brown Norway, Lewis |
| Dog | Beagle |
| Monkey | Cynomolgus, Rhesus |
| Minipig | Bama |
| Rabbit | New Zealand, Dutch-Belted |
| Feline | Chinese Domestic Cat, Maine Coon |
| Other species | LVG Hamster, Hartley Guinea Pig |
MileCell Primary Suspension Hepatocytes
MileCell provides pooled, suspension-format, metabolism-qualified hepatocytes across the animal species and strains listed in the product portfolio. The brochure presents all listed suspension products at 5 million cells and includes gender-specific or mixed-gender options where available. Product features include high post-thaw viability, key CYP/SULT/UGT characterization, large batch sizes, broad species coverage, inventory availability, and configurable options.
· Mouse and rat portfolios with multiple strains and male, female, or mixed-gender entries shown.
· Dog, monkey, minipig, rabbit, feline, hamster, and guinea pig products listed in the suspension portfolio.
· Metabolism-qualified product descriptions and functional data for CD-1 mouse suspension hepatocytes.
| Next stepExplore MileCell Primary Suspension Hepatocytes, request product information and available functional characterization, download the product brochure, or contact MileCell for current availability and technical support. |
FAQ: Suspension Hepatocytes in Drug Metabolism Testing
What are suspension hepatocytes used for?
The brochure describes suspension hepatocyte cultures for drug metabolism and uptake studies.
Which metabolic pathways are characterized?
The brochure lists characterization of key CYP, SULT, and UGT enzymes. Its CD-1 mouse data include CYP1A, CYP3A, CYP2B, CYP2C, UGT, ST, and UGT1A1 readouts.
What experimental conditions are reported for the metabolic-activity data?
CD-1 mouse suspension hepatocytes were thawed and incubated at 37°C at 0.5 x 10^6 cells/mL. Activities were measured by LC-MS/MS and reported as pmol/min/10^6 cells.
What metabolic-stability examples are provided?
The brochure presents 1 μM 7-hydroxycoumarin and 1 μM verapamil stability curves in CD-1 mouse suspension hepatocytes, with samples analyzed by LC-MS/MS over time.
Are multiple species and strains available?
Yes. The detailed suspension portfolio lists mouse, rat, dog, monkey, minipig, rabbit, feline, hamster, and guinea pig products, including multiple strains or breeds for several species.
What configuration is shown for the listed products?
The portfolio entries are described as pooled, suspension, and metabolism qualified, with a listed size of 5 million cells. Gender options vary by catalog entry.
Conclusion
Suspension hepatocytes support drug metabolism testing by combining a suspended-cell format with post-thaw quality control and functional characterization. In the MileCell brochure, the key evidence includes Phase I and Phase II enzyme-activity data across five CD-1 mouse lots, metabolic-stability curves for 7-hydroxycoumarin and verapamil, and a broad animal-species portfolio.
A practical selection process should therefore confirm the metabolic pathway of interest, the available assay evidence, species and strain, gender option, pooled format, vial size, and batch or cell-specification requirements. This approach keeps product selection aligned with the information actually available for the planned study.
Looking for suspension hepatocytes for drug metabolism testing? Explore MileCell Primary Suspension Hepatocytes, request product information and available functional characterization, or contact the MileCell team for current availability and technical support.
Contact: Info@milecell-bio.com | Website: www.milecell-bio.com
